journal article·2021-06-30Open access

Self-Assembled Nanobodies as Selectively Targeted, Nanostructured, and Multivalent Materials

Laura Sánchez-García, Eric Voltà-Durán, Eloi Parladé, Elisa Mazzega, Alejandro Sánchez-Chardi, Naroa Serna, Hèctor López-Laguna, Mara Mitstorfer, Ugutz Unzueta, Esther Vázquez, Antonio Villaverde, Ario de Marco

ACS Applied Materials & Interfaces· Volume 13· Issue 25

Abstract

Nanobodies represent valuable tools in advanced therapeutic strategies but their small size (∼2.5 × ∼ 4 nm) and limited valence for interactions might pose restrictions for in vivo applications, especially regarding their modest capacity for multivalent and cooperative interaction. In this work, modular protein constructs have been designed, in which nanobodies are fused to protein domains to provide further functionalities and to favor oligomerization into stable self-assembled nanoparticles. The nanobody specificity for their targets is maintained in such supramolecular complexes. Also, their diameter around 70 nm and multivalent interactivity should favor binding and penetrability into target cells via solvent-exposed receptor. These concepts have been supported by unrelated nanobodies directed against the ricin toxin (A3C8) and the Her2 receptor (EM1), respectively, that were modified with the addition of a reporter protein and a hexa-histidine tag at the C-terminus that promotes self-assembling. The A3C8-based nanoparticles neutralize the ricin toxin efficiently, whereas the EM1-based nanoparticles enable to selective imaging Her2-positive cells. These findings support the excellent extracellular and intracellular functionality of nanobodies organized in form of oligomeric nanoscale assemblies.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Toxin Mechanisms and Immunotoxins · Monoclonal and Polyclonal Antibodies Research · Glycosylation and Glycoproteins Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, Bellaterra, Barcelona 08193, Spain

Departament de Genètica i de Microbiologia, Universitat Autònoma de Barcelona, Bellaterra, Barcelona 08193, Spain

CIBER de Bioingeniería Biomateriales y Nanomedicina (CIBER-BBN), Bellaterra, Barcelona 08193, Spain

Laboratory for Environmental and Life Sciences, University of Nova Gorica Nova Gorica 5000, Slovenia

Servei de Microscòpia, Universitat Autònoma de Barcelona, Bellaterra, Barcelona 08193, Spain

Departament de Biologia Evolutiva, Ecologia i Ciències Ambientals, Facultat de Biologia, Universitat de Barcelona, 08028 Barcelona, Spain

University of Natural Resources and Life Sciences, Department of Chemistry, Institute of Biochemistry, 1190 Vienna, Austria

Biomedical Research Institute Sant Pau (IIB Sant Pau), Sant Antoni Ma̲ Claret 167, 08025 Barcelona, Spain

Funding

Javna Agencija za Raziskovalno Dejavnost RS · Ministerio de Ciencia, Innovaci??n y Universidades · Centro de Investigaci??n Biom??dica en Red en Bioingenier??a, Biomateriales y Nanomedicina · European Regional Development Fund · European Cooperation in Science and Technology · Instituto de Salud Carlos III · European Social Fund · Instituci?? Catalana de Recerca i Estudis Avan??ats · Agencia Estatal de Investigaci??n · Ag??ncia de Gesti?? d'Ajuts Universitaris i de Recerca

References (61)

Show source-provided references
1. 10.1186/s12934-018-0881-310.1186/s12934-018-0881-3 ↗
2. 10.1038/518027a10.1038/518027a ↗
3. 10.1016/j.jim.2018.10.01210.1016/j.jim.2018.10.012 ↗
4. 10.1038/363446a010.1038/363446a0 ↗
5. 10.1146/annurev-biochem-063011-09244910.1146/annurev-biochem-063011-092449 ↗
6. 10.1186/s12934-015-0320-710.1186/s12934-015-0320-7 ↗
7. 10.1016/j.pep.2020.10564510.1016/j.pep.2020.105645 ↗
8. 10.1016/j.antiviral.2011.09.00210.1016/j.antiviral.2011.09.002 ↗
9. 10.1007/s11248-009-9338-010.1007/s11248-009-9338-0 ↗
10. 10.1080/17512433.2019.160729310.1080/17512433.2019.1607293 ↗
11. 10.1007/s40265-018-0989-010.1007/s40265-018-0989-0 ↗
12. https://clinicaltrials.gov/. Clinical Trials. (accessed on 2020/8/5).
13. 10.1007/s00253-007-1142-210.1007/s00253-007-1142-2 ↗
14. 10.1038/nchem.281110.1038/nchem.2811 ↗
15. 10.1016/j.jconrel.2019.11.01410.1016/j.jconrel.2019.11.014 ↗
16. 10.1186/1477-3155-12-510.1186/1477-3155-12-5 ↗
17. 10.1002/smll.20120139010.1002/smll.201201390 ↗
18. 10.1038/s41467-017-00448-010.1038/s41467-017-00448-0 ↗
19. 10.1016/j.vaccine.2005.05.01710.1016/j.vaccine.2005.05.017 ↗
20. 10.1016/j.nucmedbio.2015.03.00310.1016/j.nucmedbio.2015.03.003 ↗
21. 10.1371/journal.pone.006949510.1371/journal.pone.0069495 ↗
22. 10.1158/1535-7163.MCT-07-238410.1158/1535-7163.MCT-07-2384 ↗
23. 10.1093/protein/gzm06710.1093/protein/gzm067 ↗
24. 10.1021/acs.biomac.7b0006410.1021/acs.biomac.7b00064 ↗
25. 10.1016/j.jmb.2003.09.03410.1016/j.jmb.2003.09.034 ↗
26. 10.1016/j.jim.2006.10.00610.1016/j.jim.2006.10.006 ↗
27. 10.7150/thno.5751010.7150/thno.57510 ↗
28. 10.1021/nn405573210.1021/nn4055732 ↗
29. 10.1016/j.biomaterials.2012.08.03310.1016/j.biomaterials.2012.08.033 ↗
30. 10.1007/s40843-019-9582-910.1007/s40843-019-9582-9 ↗
31. 10.1002/adma.20150367610.1002/adma.201503676 ↗
32. 10.1016/j.nano.2020.10233410.1016/j.nano.2020.102334 ↗
33. 10.1016/j.actbio.2018.10.03010.1016/j.actbio.2018.10.030 ↗
34. 10.1016/j.tibs.2020.08.00310.1016/j.tibs.2020.08.003 ↗
35. 10.1002/adfm.20210091410.1002/adfm.202100914 ↗
36. 10.1002/smll.20200188510.1002/smll.202001885 ↗
37. 10.1007/s40843-019-1231-y10.1007/s40843-019-1231-y ↗
38. 10.1016/j.actbio.2019.12.00310.1016/j.actbio.2019.12.003 ↗
39. 10.1016/j.actbio.2020.06.03310.1016/j.actbio.2020.06.033 ↗
40. 10.1016/j.mattod.2017.01.01310.1016/j.mattod.2017.01.013 ↗
41. 10.1080/19420862.2016.123688210.1080/19420862.2016.1236882 ↗
42. 10.1111/vco.1235910.1111/vco.12359 ↗
43. 10.1074/jbc.M20954820010.1074/jbc.M209548200 ↗
44. 10.3390/toxins701004910.3390/toxins7010049 ↗
45. 10.1002/smll.20180066510.1002/smll.201800665 ↗
46. 10.1016/S0968-0896(98)00061-310.1016/S0968-0896(98)00061-3 ↗
47. 10.1002/pro.292610.1002/pro.2926 ↗
48. 10.2217/nnm.09.9810.2217/nnm.09.98 ↗
49. 10.2174/13892000978989549910.2174/138920009789895499 ↗
50. 10.1007/s00216-019-01633-410.1007/s00216-019-01633-4 ↗
51. 10.7150/thno.3494110.7150/thno.34941 ↗
52. 10.1126/science.aaq062010.1126/science.aaq0620 ↗
53. 10.7554/eLife.4875010.7554/eLife.48750 ↗
54. 10.3389/fncel.2014.0034410.3389/fncel.2014.00344 ↗
55. 10.1016/j.nano.2019.10210310.1016/j.nano.2019.102103 ↗
56. 10.1016/j.jconrel.2013.08.29810.1016/j.jconrel.2013.08.298 ↗
57. 10.1021/acs.molpharmaceut.8b0131810.1021/acs.molpharmaceut.8b01318 ↗
58. 10.1074/jbc.M114.62794310.1074/jbc.M114.627943 ↗
59. 10.1038/srep0785010.1038/srep07850 ↗
60. 10.1016/j.toxicon.2010.07.00310.1016/j.toxicon.2010.07.003 ↗
61. https://www.cdc.gov/. CDC. (accessed on 2020/8/5).